The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases
AbstractDepression is common in older adults and those with cardiovascular disease. Although selective serotonin reuptake inhibitors generally have been shown to be safe to treat depression in these patients, it is important to identify additional antidepressants when selective serotonin reuptake inhibitors are not effective. This qualitative narrative review summarizes what is known about the cardiovascular side effects of some of the newer antidepressants. Twelve novel non-selective serotonin reuptake inhibitor antidepressants were identified from the literature: venlafaxine, desvenlafaxine, duloxetine, milnacipran, levo...
Source: CNS Drugs - October 16, 2020 Category: Neurology Source Type: research
Newborn with serotoninergic syndrome due to desvenlafaxine abstinence.
Authors: Sánchez Malo MJ, Hidalgo Sanz J, Curto Simón B
PMID: 32951880 [PubMed - as supplied by publisher] (Source: Medicina Clinica)
Source: Medicina Clinica - September 22, 2020 Category: General Medicine Tags: Med Clin (Barc) Source Type: research
In Vitro-In Vivo Correlation for Desvenlafaxine Succinate Monohydrate Extended Release Tablets.
The objective of this study was to develop a dissolution test in order to establish an in vitro-in vivo correlation (IVIVC) model for desvenlafaxine succinate monohydrate (DVSM) extended release (ER) tablets. The in vitro release characteristics of the drug were determined using USP apparatus 1 at 75 rpm, with volume of HCl pH 1.2, acetate buffer solution (ABS) pH 4.5, or phosphate buffer solution (PBS) pH 6.8. In vivo plasma concentrations and pharmacokinetic parameters in healthy volunteers were obtained from a bioequivalence study. The similarity factors f1 and f2 were used to compare the dissolution data. The IVIVC...
Source: AAPS PharmSciTech - July 13, 2020 Category: Drugs & Pharmacology Authors: da Silva JD, de Sousa VP, Cabral LM, Davanço MG, Meulman J, de Oliveira Carvalho P, Campos DR Tags: AAPS PharmSciTech Source Type: research
Depression in the Elderly. Consensus Statement of the Spanish Psychogeriatric Association
ConclusionsConsensus was reached for a high number of items as well as for the management of depression in the context of comorbid conditions and in resistant cases. In the current absence of sufficient evidence-based information, our results can be used to inform medical doctors about clinical recommendations that might reduce uncertainty in the diagnosis and treatment of elderly patients with depressive disorders. (Source: Frontiers in Psychiatry)
Source: Frontiers in Psychiatry - May 19, 2020 Category: Psychiatry Source Type: research
The network structure of core depressive symptom-domains in major depressive disorder following antidepressant treatment: a randomized clinical trial.
CONCLUSION: Our findings highlight the utility of focusing on the dynamic interaction between depressive symptoms to better understand how the treatment with ADs unfolds over time. In addition, depressed mood, fatigue, and cognitive/psychomotor disturbance seem to be central MDD symptoms that may be viable targets for novel, focused therapeutic interventions.
PMID: 32312344 [PubMed - as supplied by publisher] (Source: Psychological Medicine)
Source: Psychological Medicine - April 20, 2020 Category: Psychiatry Authors: Berlim MT, Richard-Devantoy S, Dos Santos NR, Turecki G Tags: Psychol Med Source Type: research
The Relationship between Plasma Serotonin and Kynurenine Pathway Metabolite Levels and the Treatment Response to Escitalopram and Desvenlafaxine
ConclusionsIn MDD patients the antidepressant response to escitalopram was positively associated with baseline serotonin levels and inversely associated with activation of the kynurenine pathway. These results appear consistent with previous literature showing that biomarker evidence of inflammation is associated with lower response to antidepressants from the selective serotonin reuptake inhibitor class. Moreover, increases in the kynurenic acid (KynA)/3-hydroxykynurenine (3HK) ratio, which previously has been characterized as a neuroprotective index, were associated with full remission under escitalopram treatment. (Sour...
Source: Brain, Behavior, and Immunity - January 21, 2020 Category: Neurology Source Type: research
The Relationship between Plasma Serotonin and Kynurenine Pathway Metabolite Levels and the Treatment Response to Escitalopram and Desvenlafaxine.
CONCLUSIONS: In MDD patients the antidepressant response to escitalopram was positively associated with baseline serotonin levels and inversely associated with activation of the kynurenine pathway. These results appear consistent with previous literature showing that biomarker evidence of inflammation is associated with lower response to antidepressants from the selective serotonin reuptake inhibitor class. Moreover, increases in the kynurenic acid (KynA)/3-hydroxykynurenine (3HK) ratio, which previously has been characterized as a neuroprotective index, were associated with full remission under escitalopram treatment.
...
Source: Brain, Behavior, and Immunity - January 20, 2020 Category: Neurology Authors: Sun Y, Drevets W, Turecki G, Li QS Tags: Brain Behav Immun Source Type: research
A Scoping Review of the Evidence Behind CYP2D6 Inhibitor Classifications.
The objective was to identify if the classification of currently listed FDA moderate and weak inhibitors is supported by publicly available primary literature. We conducted a literature search and reviewed product labels (PLs) for AUC-fold changes caused by inhibitors in humans and identified 89 inhibitor-substrate pairs. Observed AUC-fold change of the substrate was used to create an observed inhibitor classification per FDA-defined AUC-fold change thresholds. We then compared the observed inhibitor classification with the classification listed in the FDA Table of Inhibitors. We found 62% of the inhibitors within the pair...
Source: Clinical Pharmacology and Therapeutics - January 6, 2020 Category: Drugs & Pharmacology Authors: Cicali EJ, Smith DM, Duong BQ, Kovar LG, Cavallari LH, Johnson JA Tags: Clin Pharmacol Ther Source Type: research
Electrochemical treatment of real hospital wastewaters and monitoring of pharmaceutical residues by using surrogate models
Publication date: October 2019Source: Journal of Environmental Chemical Engineering, Volume 7, Issue 5Author(s): Yassine Ouarda, Florence Bouchard, Antonin Azaïs, Marc-Antoine Vaudreuil, Patrick Drogui, Rajeshwhar Dayal Tyagi, Sébastien Sauvé, Gerardo Buelna, Rino DubéAbstractThe electrochemical oxidation of drug residues in hospital wastewater has been studied. Treatment performances were evaluated by measuring the residual concentrations of twelve pharmaceutical compounds from different categories (caffeine, cihydrocarbamazepine, desvenlafaxine, sulfamethoxazole, venlafaxine, 2-hydroxy ibuprofen, carbamazepine, 4-hyd...
Source: Journal of Environmental Chemical Engineering - August 17, 2019 Category: Chemistry Source Type: research
The association between antidepressant treatment and brain connectivity in two double-blind, placebo-controlled clinical trials: a treatment mechanism study
Publication date: Available online 24 June 2019Source: The Lancet PsychiatryAuthor(s): Yun Wang, Joel Bernanke, Bradley S Peterson, Patrick McGrath, Jonathan Stewart, Ying Chen, Seonjoo Lee, Melanie Wall, Vanessa Bastidas, Susie Hong, Bret R Rutherford, David J Hellerstein, Jonathan PosnerSummaryBackgroundAntidepressant medications offer an effective treatment for depression, yet nearly 50% of patients either do not respond or have side-effects rendering them unable to continue the course of treatment. Mechanistic studies might help advance the pharmacology of depression by identifying pathways through which treatments exe...
Source: The Lancet Psychiatry - June 26, 2019 Category: Psychiatry Source Type: research
IJERPH, Vol. 16, Pages 2255: Indices of Change, Expectations, and Popularity of Biological Treatments for Major Depressive Disorder between 1988 and 2017: A Scientometric Analysis
Conclusions. This scientometric analysis represents comprehensive evidence on the popularity and change in prospects of biological treatments for MDD from 1988 to 2017. The popularity of SSRI peaked between 1998 and 2002, when their efficacy, tolerability and safety profile allowed them to replace the TCAs and MAOIs. While the newer neurostimulation therapies are gaining momentum, the popularity of ECT has sustained. (Source: International Journal of Environmental Research and Public Health)
Source: International Journal of Environmental Research and Public Health - June 25, 2019 Category: Environmental Health Authors: Bach X. Tran Giang H. Ha Giang T. Vu Long H. Nguyen Carl A. Latkin Kalpana Nathan Roger S. McIntyre Cyrus S. Ho Wilson W. Tam Roger C. Ho Tags: Article Source Type: research
Predictors of functional response and remission with desvenlafaxine 50 mg and 100 mg: a pooled analysis of randomized, placebo-controlled studies in patients with major depressive disorder.
CONCLUSION: Early improvement in SDS total score was predictive of functional outcomes for patients treated with desvenlafaxine 50 mg, desvenlafaxine 100 mg, or placebo.
PMID: 31060632 [PubMed - as supplied by publisher] (Source: CNS Spectrums)
Source: CNS Spectrums - May 6, 2019 Category: Neurology Authors: Soares CN, Wajsbrot DB, Boucher M Tags: CNS Spectr Source Type: research
